The Clinical Research Office (CRO) provides numerous services to faculty and staff conducting oncology research at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The CRO has a key leadership role in the SKCCC research infrastructure, with the CRO Director overseeing and integrating activities among the several Clinical Research Cores. The Program Managers of the seven disease-specific research Programs and the SAC lab Manager have a dual-reporting relationship to both the Research Program Directors and the CRO Manager. This allows for a centralized research infrastructure yet at the same time allows disease-specific Programs flexibility based on the disease(s) being studies. Centralized and integrated CRO electronic resources include (1) a Clinical Research Management System (CRMS) tracking real time accrual to all oncology research studies, (2) a Protocol Library containing all active protocols, consents, order sets, and related documents, (3) a Pharmacy Research Orders Tracking/Approval System (POTS), (4) the Protocol Review and Monitoring System-Clinical Research Review Committee (PRMSCRC) Electronic Forum tracking documents, scientific review comments, and meeting outcomes from the weekly pre-PRMS-CRC (pre-Protocol Review and Monitoring System) and CRC (Protocol Review and Monitoring System) meetings, (5) a Standard Operating Procedures website for housing recommended clinical research methods and procedures, (6) a Regulatory Documents Warehouse to provide centralized access to common regulatory documents including clinical investigator CVs and laboratory certifications, and (7) an external SKCCC Clinical Trials website to facilitate web-based clinical trials searches by the community. Education provided by the CRO includes an introductory research course for all new research staff involved in oncology clinical trials, CRMS training, and continuing research education for research faculty and staff. The CRO provides regulatory expertise regarding FDA regulations and Investigational New Drug (IND) submissions, and internal regulatory oversight and guidance for all investigator-initiated trials. Quality assurance services are an essential component of the CRO via auditing and monitoring and developing standard operating procedures. The CRO acts as a liaison with the Johns Hopkins Institutional Review Boards, outside auditors and regulatory agencies. In 2010, there were 499 active research studies, including 319 therapeutic (354 Intervention) clinical trials. Accruals in 2010 totaled 6,386;including 5,036 to non-intervention studies and 1,350 to intervention trials. Lay: The Clinical Research Office (CRO) provides a centralized infrastructure for the conduct of clinical trials, including formal education programs, regulatory expertise, auditing, and databases such as a Protocol Library;a Clinical Research Management System (CRMS) for tracking enrollment, and a Pharmacy Orders Tracking System (POTS). The CRO plays a key role in integrating activities among the other clinical research cores. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661002
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$588,914
Indirect Cost
$226,126
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications